How vigorously has US FDA pursued stronger compounding oversight?
This article was originally published in Scrip
Executive Summary
Even before the current meningitis outbreak, gaps in the US FDA's legal authorities in overseeing the activities of compounding pharmacies led to at least 23 deaths and 86 serious illnesses or injuries in 34 states in cases in which regulators were aware of violations, according to a new congressional report.